The role of pemetrexed combined with gemcitabine for non-small-cell lung cancer

Current Drug Targets

Volumn 11, Issue 1, 2010, Pages 61-66

  Ngeow, Joanne ^a   Toh, Chee Keong ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Gemcitabine; NSCLC; Pemetrexed

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYANOCOBALAMIN; DIHYDROFOLATE REDUCTASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FOLIC ACID; GEMCITABINE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HUMAN; LUNG NON SMALL CELL CANCER; NEUTROPENIA; OVERALL SURVIVAL; RASH; REVIEW; SIDE EFFECT; LUNG TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS;

EID: 77949458042     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010790031081     Document Type: Review

References (41)

1. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004; 292: 470-84.
2. D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005; 23: 2926-36.
3. Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2005; 21: 3025-34.
4. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57: 1116-23.
5. Shih C, Thronton DE. In: Jackman AL, Ed. Antifolate drugs in cancer therapy. Totowa, NJ, Humana Press 1999; 183-201.
6. Tonkinson JL, Marder P, Andis SL, Schultz RM, Gossett LS, Shih C, et al. Cell cycle effects of antifolate antimetabolites implications for cytotoxicity and ctostasis. Cancer Chemother Pharmacol 1997; 39: 521-31.
7. Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckardt JR, et al. Initial phase 1 evaluation of multitargeted antifolate, LY231514, administered every 21 days, utilizing the modified continual assessment method for dose escalation. J Clin Oncol 1995; 13: 2842-50.
8. McDonald AC, Vasey PA, Adams L, Walling J, Woodworth JR, Abrahams T, et al. A phase 1 and pharmacokinetic study of LY 231514, the multitargeted antifolate. Clin Cancer Res 1998; 4: 605-10.
9. Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, et al. Multitargeted antifolate LY 231514 as first line chemotherapy for patients with advanced non small cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999; 17: 1194-9.
10. Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Ann Oncol 2002; 13: 737-41.
11. Miller KD, Picus J, Blanke C, John W, Clark J, Shulman LN, et al. Phase II study of the multitargeted antifolate LY 23514 (alimta, MTA, pemetrexed disodium) in patient with advanced pancreatic cancer. Ann Oncol 2000; 11: 101-3.
12. John W, Picus J, Blanke CD, Clark JW, Schulman LN, Rowinsky EK, et al. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: Results from a phase II study. Cancer 2000; 88: 1807-13.
13. Cripps C, Burnell M, Jolivet J, Batist G, Lofters W, Dancey J, et al. Phase II study of first line LY231514 (multitargeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group Study. Ann Oncol 1999; 10: 1175-9.
14. Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002; 1: 545-52.
15. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced stage non small cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
16. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-97.
17. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995; 22: 3-10.
18. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1821-6.
19. Abratt RP,Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1535-40.
20. Gatzemeier U, Shepherd FA, le Chevalier T, Weynants P, Cottier B, Groen HJ, et al. Activity of gemcitabine in patients with non-small-cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 1996; 32A: 243-8.
21. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18: 122-30.
22. Schiller JH, Harrington D, Belani C, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
23. Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M. Synergistic cyto-toxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 2004; 10: 2936-43.
24. Giovannetti E, Nannizzi S, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small cell lung cancer cells. Mol Pharmacol 2005; 68: 110-8.
25. Ajdei AA. Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. Lung Cancer 2001; 34: S103-5.
26. Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999; 59: 3671-6.
27. Tesei A, Ricotti L, De Paola F, Amadori D, Frassineti GL, Zoli W. In vitro schedule dependent interactions between the multitarget antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines. Clin Cancer Res 2002; 8: 233-9.
28. Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, Goldberg RM, et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000; 18: 1748-57.
29. Nagai S, Takenaka K, Sonobe M, Wada H, Tanaka F. Schedule-Dependent Synergistic Effect of Pemetrexed Combined with Gemcitabine against Malignant Pleural Mesothelioma and Non-Small Cell Lung Cancer Cell Lines. Chemotherapy 2008; 54: 166-75.
30. Melemed AS, Larson T, Dudek AZ, Mellskog CE, Bloss LP, Ye Z, et al. Final report of a phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors: second dosing schedule and response. J Clin Oncol 2005; 23(16S): 7257.
31. Dy GK, Suri A, Reid JM, Sloan JA, Pitot HC, Alberts SR, et al. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tremors. Cancer Chemother Pharmacol 2005; 55: 522-30.
32. Monnerat C, Le Chevalier T, Kelly K, Obasaju CK, Brahmer J, Novello S, et al. Phase II study of pemetrexed-gemcitabine combination in patients with advanced stage non-small-cell lung cancer. Clin Cancer Res 2004; 10: 5439-46.
33. Treat J, Bonomi P, McCleod M, Christiansen MP, Mintzer DM, Monberg MJ, et al. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial. Lung Cancer 2006; 53: 77-83.
34. Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikcevich DA, Rowland KM, et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5929-37.
35. West H, Wakelee HA, Perry MC, Belt RJ, Chen R, Obasaju C. Gemcitabine and pemetrexed administered in rapid sequence as front line chemotherapy for advanced non small cell lung cancer: a phase II clinical trial. Ann of Oncol 2009; 20: 850-6.
36. Bepler G, Sommers KE, Robinson LA, Sharma A, Cantor A, Williams C, et al. Neoadjuvant gemcitabine and pemetrexed (NeoGP) in resectable non-small cell lung cancer (NSCLC). Lung Cancer 2005; 49(S2): S39 (Abstr 0-111)
37. Peterson P, Park K, Fossella F, Gatzemeier U, John W, Scagliotti G, et al. Is pemetrexed more effective in adenocarcinoma and large cell carcinoma than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007; 2(8): S851(Abstr P2-238).
38. Ciuleanu TE, Brodowicz T, Belani CP, Kim J, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A Phase III study. J Clin Oncol 2008; 26(15S): 8011.
39. Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N. Efficacy and safety of two does of pemetrexed supplemented with folic acid with vitamin B12 in previously treated patients with non small cell lung cancer. Clin Cancer Res 2008; 14: 4206-12.
40. Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 2008; 3: 1112-8.
41. Rosell R, Taron M, Sanchez JM, Moran T, Reguart N, Besse B, et al. The promise of pharmacogenomics: gemcitabine and pemetrexed. Oncology (Williston Park) 2004; 18(13 Suppl 8): 70-6.